Brief: Aim Vaccine Says Approval For Clinical Trials In China And U.S. For Vaccine
18/05/2025 23:44
May 19 (Reuters) - AIM Vaccine Co Ltd 6660.HK: APPROVAL FOR CLINICAL TRIALS IN CHINA AND U.S. FOR ITERATIVE MRNA HERPES ZOSTER VACCINE Further company coverage: 6660.HK (Reporting by Nichiket Sunil) ((Reuters.Briefs@thomsonreuters.com))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine